menu
    • menu
    [{"orgOrder":0,"company":"CRG UZ Brussel","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Lutropin Alfa","moa":"Luteinizing hormone\/Choriogonadotropin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"CRG UZ Brussel","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CRG UZ Brussel \/ Merck Group","highestDevelopmentStatusID":"11","companyTruncated":"CRG UZ Brussel \/ Merck Group"},{"orgOrder":0,"company":"IVI Fertility","sponsor":"Merck Group | Syntax for Science, S.L | Fundaci\u00f3n IVI","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Lutropin Alfa","moa":"Luteinizing hormone\/Choriogonadotropin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"IVI Fertility","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IVI Fertility \/ Merck Group | Syntax for Science, S.L | Fundaci\u00f3n IVI","highestDevelopmentStatusID":"10","companyTruncated":"IVI Fertility \/ Merck Group | Syntax for Science, S.L | Fundaci\u00f3n IVI"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Lutropin Alfa","moa":"Luteinizing hormone\/Choriogonadotropin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Merck Group"},{"orgOrder":0,"company":"Assuta Hospital Systems","sponsor":"Maccabi Healthcare Services, Israel","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"ISRAEL","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Lutropin Alfa","moa":"Luteinizing hormone\/Choriogonadotropin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Assuta Hospital Systems","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assuta Hospital Systems \/ Maccabi Healthcare Services, Israel","highestDevelopmentStatusID":"11","companyTruncated":"Assuta Hospital Systems \/ Maccabi Healthcare Services, Israel"}]

    Find Clinical Drug Pipeline Developments & Deals for Lutropin Alfa

    Menu

    Lutropin Alfa

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CRG UZ Brussel

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            CRG UZ Brussel

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutropin Alfa

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders

                            Details : Lutropin Alfa is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility, Female.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 06, 2022

                            Lead Product(s) : Lutropin Alfa

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IVI Fertility

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            IVI Fertility

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutropin Alfa

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Merck Group | Syntax for Science, S.L | Fundación IVI

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH)

                            Details : Lutropin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Infertility, Female.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 15, 2018

                            Lead Product(s) : Lutropin Alfa

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Merck Group | Syntax for Science, S.L | Fundación IVI

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Assuta Hospital Systems

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Assuta Hospital Systems

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutropin Alfa

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Maccabi Healthcare Services, Israel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Severe LH Suppressed Patients After Administration of a GnRH Antagonist

                            Details : Lutropin Alfa is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility, Female.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 05, 2013

                            Lead Product(s) : Lutropin Alfa

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Maccabi Healthcare Services, Israel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Merck Group

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutropin Alfa

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women Wit...

                            Details : Lutropin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypogonadism.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 10, 2010

                            Lead Product(s) : Lutropin Alfa

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth